期刊文献+

广州市肾细胞癌医保患者直接经济负担研究

Disease Economic Burden of Insured Patients with Renal Cell Carcinoma in Guangzhou
下载PDF
导出
摘要 目的从社会角度探讨广州市肾细胞癌疾病经济负担情况。方法对广州市2010—2012年有关肾癌医保患者数据进行描述性统计分析,计算肾癌的直接经济负担,利用分类树进行影响因素分析。结果 2010—2012年广州市肾癌患者的直接经济负担分别是430万元、707万元、1 131万元。肾癌门诊患者和住院患者的药品费用分别占总医疗费用的47%和46%。住院患者的总医疗费用占肾癌直接经济负担的98%。肾癌患者的就诊类型、性别、年龄对总医疗费用影响较大。性别和年龄对门诊患者的次均总医疗费用影响较大,住院天数和是否手术对住院患者的次均总医疗费用影响较大。结论肾癌就诊人次逐年增多,直接经济负担也明显上升。 Objectives To evaluate the disease economic burden of renal cell carcinoma(RCC)from a social point.Methods The study used the 2010-2012 Medical Insurance Database from Guangzhou to calculate the direct economic burden of RCC and carried on influencing factor analysis by classification trees.Results From 2010to2012,Guangzhou's direct medical costs of RCC were 4.30 million yuan,7.07 million yuan and 11.31 million yuan.Outpatients' drug costs occupied 47% of the total medical expenses and this number for inpatients was 46%.Inpatients' total medical expenses occupied 98% of the direct economic burden of RCC.Gender and age of patients had a greater influence on the total medical costs.Hospitalization days and whether to operate of hospitalized patients had greater influence on the total medical costs.Conclusions Attendances increased year by year due to RCC and the direct economic burden increased significantly.
出处 《中国社会医学杂志》 2017年第1期33-37,共5页 Chinese Journal of Social Medicine
基金 广州市医药卫生科技重大项目(20121A031004)
关键词 肾细胞癌 经济负担 分类树 Renal cell carcinoma Economic cost Classification trees
  • 相关文献

参考文献4

二级参考文献32

  • 1杜贤进,张杰.分子靶向药物舒尼替尼治疗肾细胞癌[J].世界临床药物,2009,30(11):657-661. 被引量:3
  • 2杜林栋,王文营.肾癌的分子靶向治疗[J].临床泌尿外科杂志,2007,22(10):721-724. 被引量:4
  • 3中国统计局.2012广州统计年鉴[M].北京:中国统计局出版社,2012.
  • 4胡善联.疾病经济负担的调查研究方法[J].中国卫生经济,1991,11(2):45-47.
  • 5世界卫生组织.精神卫生政策与服务指南-精神障碍的经济和社会负担[M].新加坡:世界卫生组织,2003:1-33.
  • 6Wang W B, W. McGreevey W P, Fu C W, et al. Type 2 Diabetes mellitus in China: a preventable economic burden [J]. The American Journal of Managed Care, 2009,15(9): 593- 601.
  • 7Gupta. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev,2008,34(3): 193-205.
  • 8Kang,S.,A.G. Bader,P.K. Vogt.Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A,2005,102(3): 802-807.
  • 9Mulders,P. .Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. BJU Int,2009,104(11): 1585-1589.
  • 10Sutent S.Summary of product characteristics.Pfizer Inc,2008.

共引文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部